Danaher Gets FTC Approval For $21B GE Biopharma Deal
The Federal Trade Commission announced a divestiture deal late Thursday that would clear Danaher to buy General Electrics' biopharma portfolio for $21.4 billion, provided the companies complete a previously disclosed sale...To view the full article, register now.
Already a subscriber? Click here to view full article